TG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Moderate Buy consensus from six analysts (2 holds, 3 buys, 1 strong buy) with an average 1‑year price target of $50.
• Recent analyst action is mixed — Goldman Sachs raised its target to $39 (neutral), JPMorgan trimmed its target to $46 but kept an overweight rating, and Wall Street Zen downgraded the stock to hold.
• Shares opened at $33.58 with a market cap of $5.36 billion; TG Therapeutics missed Q4 EPS ($0.14 vs. $0.35 expected) while revenue rose 78% YoY, and institutional investors own about 58.58% of the stock, including a new ~$57.3M stake by Congress Asset Management.

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the six ratings firms that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $50.00.

Several brokerages have weighed in on TGTX. The Goldman Sachs Group upped their target price on TG Therapeutics from $37.00 to $39.00 and gave the stock a "neutral" rating in a research report on Thursday, January 15th. Wall Street Zen lowered TG Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, February 14th. JPMorgan Chase & Co. dropped their target price on TG Therapeutics from $49.00 to $46.00 and set an "overweight" rating on the stock in a research report on Monday, February 2nd. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of TG Therapeutics in a research report on Wednesday, January 14th.

TG Therapeutics Stock Down 2.9%

NASDAQ:TGTX opened at $33.58 on Thursday. The firm has a market capitalization of $5.36 billion, a price-to-earnings ratio of 12.12 and a beta of 1.76. TG Therapeutics has a 1-year low of $25.28 and a 1-year high of $46.48. The company has a current ratio of 4.10, a quick ratio of 3.29 and a debt-to-equity ratio of 0.38. The business's fifty day moving average price is $32.02 and its 200 day moving average price is $31.50.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.35 by ($0.21). TG Therapeutics had a return on equity of 101.12% and a net margin of 72.56%.The firm had revenue of $192.57 million during the quarter, compared to analyst estimates of $192.15 million. During the same period in the previous year, the company earned $0.15 earnings per share. The business's revenue for the quarter was up 78.0% on a year-over-year basis. On average, sell-side analysts forecast that TG Therapeutics will post 1.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of TGTX. Congress Asset Management Co. acquired a new position in shares of TG Therapeutics during the 4th quarter valued at about $57,307,000. Nordea Investment Management AB acquired a new position in shares of TG Therapeutics during the 4th quarter valued at about $2,356,000. Penn Capital Management Company LLC increased its holdings in shares of TG Therapeutics by 17.6% during the 3rd quarter. Penn Capital Management Company LLC now owns 521,260 shares of the biopharmaceutical company's stock valued at $18,877,000 after acquiring an additional 77,895 shares during the last quarter. Public Sector Pension Investment Board increased its holdings in shares of TG Therapeutics by 14.5% during the 3rd quarter. Public Sector Pension Investment Board now owns 529,271 shares of the biopharmaceutical company's stock valued at $19,120,000 after acquiring an additional 66,911 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of TG Therapeutics by 56.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 227,934 shares of the biopharmaceutical company's stock valued at $8,234,000 after acquiring an additional 81,907 shares during the last quarter. 58.58% of the stock is owned by institutional investors and hedge funds.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company's research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.